Shareholder Analyst Call

Insights PSMAfore trial design BPI-SF pain intensity scale2 HR: 0.69 (95% CI: 0.56, 0.85) Novartis Investor Relations Investor Presentation October 24, 2023 This presentation contains forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995, that can generally be identified by words such as "potential," "will," "planned," "pipeline," "outlook," or similar expressions, or by express or implied discussions regarding potential marketing approvals, new ...